Table 3 Effect of trichlormethiazide on health-related quality of life.

From: The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial

Variables

Trichlormethiazide− 

Trichlormethiazide+ 

value

KDQOL

Symptoms/problems

79.4 ± 16.6

86.4 ± 10.3

0.11

Effects of kidney disease

83.1 ± 15.9

95.0 ± 5.6

0.02

Burden of kidney disease

60.6 ± 21.1

67.5 ± 23.5

0.28

Work status

95.0 ± 15.8

95.0 ± 15.8

1

Cognitive function

89.3 ± 13.0

86.7 ± 25.3

0.61

Quality of social interaction

85.3 ± 19.6

84.0 ± 25.0

0.78

Sleep

57.8 ± 22.1

70.0 ± 16.5

0.07

Social support

88.3 ± 27.3

84.2 ± 12.7

0.64

Overall health rating

62.0 ± 18.7

67.0 ± 18.9

0.27

KDCS

79.9 ± 12.1

83.6 ± 10.7

0.19

SF-36

Physical functioning

87.5 ± 19.0

90.5 ± 8.6

0.43

Physical role functioning

83.8 ± 18.2

92.5 ± 11.7

0.21

Body pain

67.9 ± 24.7

69.6 ± 27.9

0.87

General health

48.2 ± 16.4

55.6 ± 16.4

0.2

Vitality

63.1 ± 12.3

70.0 ± 15.3

0.13

Social functioning

86.3 ± 17.1

95.0 ± 8.7

0.02

Emotional role functioning

84.2 ± 16.4

95.8 ± 9.0

0.02

Mental health

75.5 ± 18.6

82.5 ± 14.4

0.23

PCS

44.2 ± 11.3

44.7 ± 8.4

0.88

MCS

49.3 ± 6.5

51.7 ± 8.7

0.28

RCS

51.9 ± 9.9

57.3 ± 5.8

0.04

  1. KDQOL Kidney Disease Quality of Life, KDCS kidney disease component summary, SF-36 Medical Outcomes Study 36-Item Short Form Health Survey MOS, PCS physical component summary, MCS mental component summary, RCS role/social component summary.